Antibiotic testing in shrimp
Seafood is one of the most important exports in India with its shrimp being a staple food in many countries worldwide. However, 2017 and 2018 saw 27 shipments of shrimp refused entry into the US by the FDA. This was followed closely in January 2019, when 26 lines were refused due to the presence of two banned antibiotics, nitrofurans and chloramphenicol.
With Indian shrimp accounting for around one third of the countries seafood exports, India has expressed its concern over the rejections. It responded by calling the tests on the products ‘too stringent’.
The global shrimp industry is estimated to be worth around $30 billion and India’s market share is estimated at 13% in value terms.
Dr. Ramraj, President of the All Indian Shrimp Hatcheries Association has stated, “some of the metabolites in shrimp and crustacean shells are known to mimic antibiotics and therefore could give false results”.
The use of antibiotics in shrimp farming in India is banned. Madhusudano Rao, Principal scientist at India’s Central Institute of Fisheries Technology has said, “All shrimp hatchery operators and shrimp farmers and advised to use only these antibiotic- free inputs during shrimp farming”.
Randox Food Diagnostics offer the most comprehensive range of ELISA and Biochip tests currently on the market, specifically designed to identify and detect the smallest traces of the most prevalent antibiotics used in seafood, including nitrofurans and chloramphenicol.
World-leading medical diagnostics manufacturer Randox Laboratories is this week showcasing advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois.
The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase their capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.
“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr Peter FitzGerald.
“At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analysers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”
The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.
Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services.
Dr. FitzGerald continued;
“We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.
“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.
“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilised to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionise the future of healthcare.”
AACC runs from the 29th July – 2nd August at McCormick Place in Chicago, Illinois. Randox can be found at booth #3624.
For further information visit aacc.randox.com
Global healthcare company Randox, which is headquartered in Co Antrim and has key R&D, engineering and manufacturing facilities in both Co Antrim and Co Donegal, has been named in The US-Ireland Top 50 Companies, to be announced today, Friday 16th June, at the New York/New Belfast conference in Manhattan.
With a focus on the transatlantic operations building bridges between the two countries, the awards celebrate those bringing business in Ireland to global heights in the belief that by doing so they are embedding peace for future generations.
The 50 honourees will be announced at a gala event hosted by the Irish Echo, the USA’s largest and most widely read Irish American weekly paper, at Pier A, Harbor House.
The tenth annual celebration will be addressed by Constance Hunter, Chief Economist of KPMG and Daniel Dromm, NYC City Council member and Chair of the Education Committee, and takes place as part of the two-day conference. This prestigious event highlights the progress and prosperity of both cities, and looks optimistically to the future while celebrating our shared past.
Movie makers, scientists, tech companies and engineers have been among those who have received the plaudit in recent years. They have included the all-conquering production company, HBO; leading law firm A&L Goodbody; pioneers in scientific imaging Andor Technology and the New York Stock Exchange.
This year’s US-Ireland Top 50 has proven to be just as illustrious with Randox Laboratories, Northern Property, Norwegian Airlines, and Bank of Ireland as just some of the companies being recognised for their success.
Editor of the Irish Echo, Ray O’Hanlon, who will host Friday’s event, said the awards were an acknowledgment of the unique bonds between the two nations.
“The unmistakable and unbreakable bonds between Ireland and the United States have proven a key element in Ireland’s progression, both in terms of peace and prosperity. Those bonds grow ever stronger when underpinned by economic growth and business relationships. With the Ireland-US Top 50 we acknowledge those companies whose transatlantic operations support that ongoing development and welcome them to this illustrious list of business beacons.”
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“The US is one of our most important markets and we have been exporting our diagnostic products there since the early 1980s. We have seen substantial success in this market and have secured for example, key clinical chemistry analyser contracts in Ivy League Institutions such as Yale University School of Medicine and Harvard University.
“Our diversification into the veterinary, research, forensic and food safety sectors has enabled our operations in the US to expand further still, and due to this increasing demand for Randox innovations, we are developing a new facility in the Greater Washington DC area.
“It is a tribute to the entire Randox team, both in Co Antrim and Co Donegal, that we have been named as one of the US-Ireland Top 50. We hope to serve as an example to other aspiring businesses that success is possible with a unique product offering, a commitment to investment, and making use of the support network available across the United States.”
For further information about the New York New Belfast Conference contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com